The Product Report was designed to provide pediatricians with up-to-date information on new medical equipment, office accessories, etc. Listings are made up from unsolicited press releases from the manufacturer. They are neither advertisements nor endorsements
Diaper Guard Skin Rash Ointment
Commerce Drug Company, a division of Del Laboratories, Farmingdale, NY introduced Diaper Guard Therapeutic Skin Rash Ointment.
Diaper Guard blocks the wetness that starts diaper rash and soothes and helps heal an existing rash. The key to the superior efficacy of Diaper Guard is its unique formula containing dimethicone and petrolatum which provides a wetness barrier that is unsurpassed.
Diaper Guard is available in 1.75 and 3.5 oz. sizes. Extra "Early Buy" discounts are available, as well as special introductory dating. An introductory prepack display is also available containing six pieces of each size, a shelf pad with Save Sl. 00 coupons, and a window streamer.
Details are available from Commerce sales representatives.
Chewable Acetaminophen Tablets
Mead Johnson Nutritionals introduced Double-Strength Tempra® Tablets, the only chewable 160 mg acetaminophen on the market.
Grape-flavored Double-Strength Tempra® Chewable Tablets were introduced so that children ages 6 to 14 can ingest fewer tablets to meet the recommended dose. In most cases, children prefer the grape flavor over any other fruit flavor. In addition, 65% of the mothers surveyed by Mead Johnson said they would choose a grape-flavored chewable double-strength tablet over their current brand for children ages 6 to 14.
Double-Strength Tempra® Chewable Tablets packaging is distinguishable from Tempra® Chewable Tablets by its purple and white box. Double-Strength Tempra® will be available in pharmacies, food stores, and most large retail outlets.
Topical Steroid for Children
Allen & Hanburys. Division of Glaxo Inc., will market Beconase® (beclomethasone dipropionate, USP) Nasal Inhaler, its anti-inflammatory topical steroid, for use in children 6 years and over. Beconase has been available in the United States since 1982 for the relief of seasonal and perennial allergic rhinitis, indicated in patients 12 years and over.
Approximately 40 million Americans, many of them children, suffer from allergies. Seasonal rhinitis - more commonly known as hay fever - occurs primarily in spring and late summer and is caused by ragweed, tree, and grass pollen. Perennial rhinitis is a year-round condition caused by such allergens as dust, mold, and animal danders.
The inhaled-steroid approach to perennial and seasonal rhinitis is relatively new in the United States. Many doctors favor this treatment in patients over the use of antihistamines and decongestants, which can cause drowsiness, rebound congestion, and cardiovascular stimulation. Beconase has minimal systemic side effects at recommended doses.